Perspectives on 2019’s New Hematology Drug Approvals
In 2019, the FDA approved several new therapies – or new indications for previously approved therapies – for people living with blood disorders, including...
Updates on ASH Clinical Practice Guidelines in Development
In 2019, the American Society of Hematology (ASH) continued its efforts to develop and publish evidence-based clinical practice guidelines to help practicing hematologists and...
FDA Approves Voxelotor for Sickle Cell Disease
The FDA has approved voxelotor, a once-daily oral therapy that modulates hemoglobin affinity for oxygen by binding to hemoglobin S and stabilizing it, to...
Crizanlizumab-tmca Becomes First Approved Targeted Therapy for Sickle Cell Disease
The FDA approved crizanlizumab-tmca to reduce the frequency of vaso-occlusive crisis in patients aged 16 and older with sickle cell disease (SCD). The agent...
Gene Editing Therapy Shows Early Benefit for Patients With SCD and Beta Thalassemia
CRISPR Therapeutics and Vertex Pharmaceuticals have reported that the first two patients to receive an experimental gene editing treatment for SCD and beta thalassemia...
Luspatercept-aamt Approved to Treat Anemia in Beta Thalassemia
The FDA approved luspatercept-aamt for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.
The approval...
BCL11A: A New Gene Therapy Target in Sickle Cell Disease?
A BCL11A-targeting gene therapy in patients with sickle cell disease (SCD) led to higher levels of fetal hemoglobin (HbF) and reductions in the severity...
Romiplostim and Eltrombopag Beat Rituximab for Secondline Chronic Immune Thrombocytopenia Treatment
After frontline treatment with corticosteroids fails to elicit a response in patients with chronic immune thrombocytopenia (cITP), the choice between rituximab or thrombopoietin receptor...
How I Treat in Brief: Venous Thromboembolism in Sickle Cell Disease
Arun S. Shet, MD, from the NIH’s National Heart, Lung, and Blood Institute, and Ted Wun, MD, from UC Davis Comprehensive Cancer Center in...
Updated Romiplostim Label Supports Earlier Use in ITP
The U.S. Food and Drug Administration (FDA) granted approval to a supplemental Biologics License Application for romiplostim that updates the drug’s label to include...
Current Issue
January 2020 Annual Meeting Edition
This issue features highlights from the 2019 ASH Annual Meeting, reflections on physician wellness, and more.
